All News
Do you work up pt with frequent infections who has RA SLE or vasculitis? Common variable immune deficiency is .....COMMON @RWCSmtg @RheumNow #RWCS2020 https://t.co/CNHsayBst5
Janet Pope Janetbirdope ( View Tweet)
If asthma and allergies ask about atopic dermatitis. Most are kid onset but continue or recur in adulthood. Tip atopic dermatitis can increase with TNFis. New Rx and JAKis are entering this disease too. George Martin #RWCS2020 @RheumNow https://t.co/HqU05h5Vkb
Janet Pope Janetbirdope ( View Tweet)
Dr. Postolova recommends checking immunoglobulins and flow cytometry on every patient prior to starting RTX. #RWCS2020 @RheumNow @RWCSmtg
Dr. Rachel Tate uptoTate ( View Tweet)
Sarcoid and CVID can look alike as both get Granulomatous lessons. Dr Anna Postolova at #RWCS2020 @RWCSmtg https://t.co/TREQwYYrgc
Dr. John Cush RheumNow ( View Tweet)
A high percentage of complement deficiencies will develop lupus. Dr Anna Postolova at #RWCS2020 @RWCSmtg https://t.co/IItg1Ezd3F
Dr. John Cush RheumNow ( View Tweet)
Common immunodeficies. Dr Anna Postolova at #RWCS2020 @RWCSmtg https://t.co/rpjrmcl8t6
Dr. John Cush RheumNow ( View Tweet)
Was are placebo responses so high in RA MTX-IR who receive MTX in RCTs. ?adherence ?placebo effect ?keen study personnel. Filgo vs Ada - both effective and not stat different but high placebo too added to MTX. #RWCS2020 @RWCSmtg @RheumNow https://t.co/hHPR9yO0gb
Janet Pope Janetbirdope ( View Tweet)
Fewer VTE and HZ in filgotinib trials. More studies needed for proof of efficacy. Drs. Fleischmann and Genovese. #RWCS2020 @RheumNow @RWCSmtg https://t.co/O50yPwTxmm
Dr. Rachel Tate uptoTate ( View Tweet)
Here’s what I think is missing in RA for JAKi trials. Mono therapy post MTX-IR vs TNFi. Comparisons head2head with other biological and post JAKi RCT of another JAKi. @RWCSmtg @RheumNow #RWCS2020 #JAK
Janet Pope Janetbirdope ( View Tweet)
Fenebrutinib, a BTK inhibitor, is better that placebo, but not ADA when given in a phase 2 trial. Drs. Fleischman/Genovese at #RWCS2020 @RWCSmtg https://t.co/lOtFoB80s3
Dr. John Cush RheumNow ( View Tweet)
Do we need another IL6 inhibitor for rheumatic diseases. Tocilizumab is off patent in USA and Europe. We have Sarilumab but Sirukumab did not go forward in RA. Another kid on block - Olokizumab IL6 receptor blocker with +RA RCT #RWCS2020 @RWCSmtg @RheumNow https://t.co/OwhnRjwPrt
Janet Pope Janetbirdope ( View Tweet)
Sky kinases are terminally sick. DNR for RA trials. Another one bites the dust. @RWCSmtg @RheumNow #RWCS2020 https://t.co/GbnEfkOR7p
Janet Pope Janetbirdope ( View Tweet)
Learning from rheum colleagues @RWCSmtg upadacitinib rate of vte similar to adalimumab and mtx. Suggests it’s the disease rather than the drug. https://t.co/KG8CionFbN
Uma Mahadevan UmaMahadevanIBD ( View Tweet)
“Autoimmunity can be the initial presentation of immunodeficiency.” Dr. A. Postolova #RWCS2020 @RheumNow @RWCSmtg
Dr. Rachel Tate uptoTate ( View Tweet)
25% of PID pts will develop an autoimmune disease. Here are Dr. Postolova’s 10 warning signs. Left for children and right for adults. #RWCS2020 @RheumNow @RWCSmtg https://t.co/mxQ2urQQ9G
Dr. Rachel Tate uptoTate ( View Tweet)
Primary immunodeficiency warning signs in adults; 25% of OID will develop an autoimmune disease. Dr Anna Postolova at #RWCS2020 @RWCSmtg https://t.co/c84Sybg95W
Dr. John Cush RheumNow ( View Tweet)
Fenebrutinib, a BTK inhibitor, is better that placebo, but not ADA when given in a phase 2 trial. Drs. Fleischman/Genovese at #RWCS2020 @RWCSmtg https://t.co/lOtFoB80s3
Dr. John Cush RheumNow ( View Tweet)
A favorable safety profile for Filgotinib, maybe less zoster and VTE. Drs. Fleischman/Genovese at #RWCS2020 @RWCSmtg https://t.co/yNn8tl3R8c
Dr. John Cush RheumNow ( View Tweet)
Finch 3 trial in MTX naive pts shows that mono Rx FIL 200=MTX mono for ACR20 but FIL200 superior for ACR50/70. 200mg works faster with more big responders early. Drs. Fleischman/Genovese at #RWCS2020 @RWCSmtg https://t.co/msgB6DS5cl
Dr. John Cush RheumNow ( View Tweet)
Finch 1 trial of Filgotinib vs adalimulmab in MTX IR #RA pts shows FIL 200 is superior to FIL 100 or ADA 40. Drs. Fleischman/Genovese at #RWCS2020 @RWCSmtg https://t.co/rMLtnLK73B
Dr. John Cush RheumNow ( View Tweet)